NDAORALTABLET
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CARTROL (carteolol hydrochloride) by AbbVie is clinical pharmacology carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Approved for hypertension, glaucoma. First approved in 1988.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Carteolol hydrochloride is a nonselective beta-adrenergic blocking agent with intrinsic sympathomimetic activity used to treat hypertension and glaucoma. It reduces intraocular pressure and blood pressure by blocking beta-adrenergic receptors, with a median IOP reduction of 22-25% when dosed topically twice daily. The drug has been approved since 1988 and is available as an oral tablet.
LOE Approaching
As LOE approaches, the CARTROL brand team is likely consolidating resources and preparing for generic erosion; expect smaller commercial footprint and reduced hiring.
Mechanism of Action
CLINICAL PHARMACOLOGY Carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Carteolol Hydrochloride reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by…
Indications (2)
Worked on CARTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.